The Readout Loud
403: Biotech exec Jeremy Levin on the industry's strategic turning point
STAT's biotech podcast covers Eli Lilly's gene-editing cholesterol drug data going viral, ASCO conference previews, and an interview with biotech executive Jeremy Levin about his new book arguing that American biotech leadership is endangered by institutional decay, short-term investing, FDA upheaval, and China's strategic rise.
402: Guarding biotech from China and big bets in longevity
This episode of The Readout Loud covers highlights from STAT's Breakthrough Summit West in San Francisco, including discussions on FDA leadership, biotech competition with Chinese companies, Eli Lilly's obesity drug data, and a detailed interview with Retro Biosciences CEO Joe Betz-Lacroix about his longevity company's clinical progress and fundraising plans.
401: Makary’s departure and Cassidy’s tenuous Senate seat
This episode of The Readout Loud covers FDA Commissioner Marty Makary's resignation and his replacement by acting commissioner Kyle Diamantis, alongside the political vulnerability of Senate Health Committee Chair Bill Cassidy ahead of a Louisiana Republican primary. The hosts and DC correspondents Lizzie Lawrence and Chelsea Ceruzzo analyze how vaping policy, abortion politics, and Trump loyalty shaped both developments.